Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
ROIV Stock Chart & Stats
$22.53
-$0.41(-3.60%)
At close: 4:00 PM EST
$22.53
-$0.41(-3.60%)
Day’s Range― - ―
52-Week Range$8.73 - $23.91
Previous CloseN/A
Volume1.46M
Average Volume (3M)6.54M
Market Cap
$15.81B
Enterprise Value$14.53B
Total Cash (Recent Filing)$4.39B
Total Debt (Recent Filing)$98.85M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Feb 06, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding695,491,640
10 Day Avg. Volume5,539,406
30 Day Avg. Volume6,542,523
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)1.56
Price to Sales (P/S)251.93
P/FCF Ratio-8.67
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue714.80
Enterprise Value/Gross Profit741.39
Enterprise Value/Ebitda-14.58
Forecast
1Y Price Target
$27.63Price Target Upside22.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet / Cash RunwayCompany's cash balance of $4.4 billion supports a runway to profitability and enables selective funding of product launches and strategic acquisitions.
Graves’ Disease Clinical PositioningEncouraging remission data from a Phase 2 batoclimab study add validation for IMVT-1402 and strengthen its positioning as a potential disease‑modifying therapy in Graves' disease if pivotal trials read out successfully.
Regulatory ProgressPhase 3 success in dermatomyositis positions brepocitinib for an NDA filing and potential priority review, increasing the likelihood of a first‑in‑class approval.
Bears Say
Clinical Data Timing UncertaintyPostponement of topline results for the Phase 3 batoclimab trials in TED for competitive reasons creates uncertainty around development timelines and could delay regulatory and commercial planning.
Revenue PerformanceReported revenue of $1.6 million, a roughly 65% year‑over‑year decline and below estimates, highlights weak near‑term commercial traction and increases reliance on pipeline milestones.
Roivant Sciences News
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $8.73 and its highest was $23.91 in the past 12 months.
What is Roivant Sciences’s market cap?
Roivant Sciences’s market cap is $15.81B.
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Feb 06, 2026 which is in 8 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Nov 10, 2025. The company reported -$0.202 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.118.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -0.3.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 695,491,640 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.202 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went up 2.667%.
Which hedge fund is a major shareholder of Roivant Sciences?
Currently, no hedge funds are holding shares in ROIV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roivant Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.63 (22.61% Upside)
$27.63 (22.61% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 12.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $382.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 8.6%
Last 30 Days ▲ 8.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.49%
12-Months-Change
Fundamentals
Return on Equity
-14.73%
Trailing 12-Months
Asset Growth
-18.42%
Trailing 12-Months
Company Description
Roivant Sciences
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
ROIV Company Deck
ROIV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and clinical progress with multiple high-impact data readouts (notably brepocitinib VALOR in dermatomyositis and durable batoclimab signals in Graves'), a deep late-stage pipeline, strong cash ( $4.4B ) and clear near-term regulatory and commercial catalysts. Offsetting risks include competitive intensity in Graves' and TED, litigation uncertainty (Moderna/Pfizer LNP cases), small sample sizes in some proof-of-concept cohorts, and translatability risks for certain programs (e.g., mosli in PH-ILD). Overall, the highlights — including positive pivotal data, pipeline breadth and a strong balance sheet — outweigh the notable but manageable risks described.View all ROIV earnings summariesROIV Stock 12 Month Forecast
Average Price Target
$27.63
▲(22.61% Upside)
Technical Analysis
Ownership Overview
21.34% Insiders
14.09% Mutual Funds
1.02% Other Institutional Investors
50.92% Public Companies and
Individual Investors